Trial Profile
An Open-label Study to Investigate the Efficacy and Tolerability of Aczone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2022
Price :
$35
*
At a glance
- Drugs Dapsone (Primary)
- Indications Acne vulgaris; Hyperpigmentation
- Focus Therapeutic Use
- 10 Feb 2022 Status changed from active, no longer recruiting to completed.
- 31 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 May 2021.
- 31 Dec 2020 Planned primary completion date changed from 1 Dec 2020 to 1 May 2021.